撤回：基于列线图的原发性骨弥漫性大B细胞淋巴瘤患者总生存和癌症特异性生存预测：一项基于人群的研究。
Retracted: Nomogram-Based Prediction of Overall and Cancer-Specific Survival in Patients with Primary Bone Diffuse Large B-Cell Lymphoma: A Population-Based Study.
作者信息
And Alternative Medicine Evidence-Based Complementary
出版信息
Evid Based Complement Alternat Med. 2023 Oct 4;2023:9848230. doi: 10.1155/2023/9848230. eCollection 2023.
Abstract
[This retracts the article DOI: 10.1155/2022/1566441.].
摘要
[本文撤回文章DOI: 10.1155/2022/1566441。]
相似文献
1
Retracted: Nomogram-Based Prediction of Overall and Cancer-Specific Survival in Patients with Primary Bone Diffuse Large B-Cell Lymphoma: A Population-Based Study.撤回：基于列线图的原发性骨弥漫性大B细胞淋巴瘤患者总生存和癌症特异性生存预测：一项基于人群的研究。
Evid Based Complement Alternat Med. 2023 Oct 4;2023:9848230. doi: 10.1155/2023/9848230. eCollection 2023.
2
Dynamic prediction of long-term survival in patients with primary gastric diffuse large B-cell lymphoma: a SEER population-based study.基于 SEER 人群的研究：原发性胃弥漫大 B 细胞淋巴瘤患者长期生存的动态预测。
BMC Cancer. 2019 Sep 3;19(1):873. doi: 10.1186/s12885-019-5993-6.
3
Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.弥漫性大 B 细胞淋巴瘤患者总生存的预后列线图。
Oncologist. 2019 Nov;24(11):e1251-e1261. doi: 10.1634/theoncologist.2018-0361. Epub 2019 Apr 5.
4
Retracted: Nomogram to Predict Overall and Cancer-Specific Survival in Patients with Synovial Sarcoma in the Extremities: A Population-Based Study.撤回：预测四肢滑膜肉瘤患者总生存和癌症特异性生存的列线图：一项基于人群的研究。
Comput Intell Neurosci. 2023 Mar 1;2023:9861979. doi: 10.1155/2023/9861979. eCollection 2023.
5
Retracted article: Adjuvant radiotherapy in patients with diffuse large B-cell lymphoma in advanced stage (III/IV) improves the outcome in the rituximab era.撤稿文章：晚期（III/IV期）弥漫性大B细胞淋巴瘤患者的辅助放疗在利妥昔单抗时代可改善预后。
Hematology. 2019 Dec;24(1):521-525. doi: 10.1080/10245332.2018.1423880. Epub 2018 Jan 17.
6
Retracted: LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.撤回：LAG3和PD1调节弥漫性大B细胞淋巴瘤患者的CD8 + T细胞。
Comput Math Methods Med. 2023 Sep 27;2023:9831240. doi: 10.1155/2023/9831240. eCollection 2023.
7
Retracted: Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL).撤回：弥漫性大B细胞淋巴瘤（DLBCL）中CD47的治疗策略。
Dis Markers. 2023 Jul 12;2023:9826727. doi: 10.1155/2023/9826727. eCollection 2023.
8
Nomogram based on the systemic immune-inflammation index for predicting the prognosis of diffuse large B-cell lymphoma.基于全身免疫炎症指数的列线图预测弥漫性大B细胞淋巴瘤的预后
Asia Pac J Clin Oncol. 2023 Apr;19(2):e138-e148. doi: 10.1111/ajco.13806. Epub 2022 Jun 26.
9
Retracted: Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma.撤回：初治同时性滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤不良预后因素筛查及预后指数构建
Biomed Res Int. 2023 Dec 29;2023:9816943. doi: 10.1155/2023/9816943. eCollection 2023.
10
Retracted: Analysis of the Correlation of Basic Fibroblast Growth Factor in Serum of Patients with Diffuse Large B-Cell Lymphoma with Clinicopathological Efficacy and International Prognostic Index.撤稿：弥漫性大B细胞淋巴瘤患者血清碱性成纤维细胞生长因子与临床病理疗效及国际预后指数的相关性分析。
Contrast Media Mol Imaging. 2023 Sep 27;2023:9828072. doi: 10.1155/2023/9828072. eCollection 2023.
引用本文的文献
1
Competing risk nomogram for predicting cancer-specific survival in patients with primary bone diffuse large B-cell lymphoma: a SEER-based retrospective study.预测原发性骨弥漫性大B细胞淋巴瘤患者癌症特异性生存的竞争风险列线图：一项基于监测、流行病学和最终结果（SEER）数据库的回顾性研究
Front Med (Lausanne). 2025 May 12;12:1572919. doi: 10.3389/fmed.2025.1572919. eCollection 2025.
本文引用的文献
1
Nomogram-Based Prediction of Overall and Cancer-Specific Survival in Patients with Primary Bone Diffuse Large B-Cell Lymphoma: A Population-Based Study.基于列线图预测原发性骨弥漫性大B细胞淋巴瘤患者的总生存期和癌症特异性生存期：一项基于人群的研究
Evid Based Complement Alternat Med. 2022 May 5;2022:1566441. doi: 10.1155/2022/1566441. eCollection 2022.
Zotero 插件